Lactabico, a biotech startup that’s part of the international Lactocore Group based in the U.S., is at the forefront of pioneering research on milk peptides. The team believes that a new generation of safer and more effective treatments for depression, anxiety, and diabetes will be derived from milk – a rich natural source of soothing and balancing bioactive components that have shown potential therapeutic properties. Utilizing proprietary computational tools, Lactabico has discovered a range of promising milk-derived peptides, two of which have already demonstrated proof-of-concept in late-stage preclinical studies. As of today, the Lactocore Group has filed three patent applications related to peptide therapeutic agents, with the most recent one submitted in 2022.